心脏科随访与心力衰竭结局改善:法国全国队列研究
该法国全国队列纳入近5年报告心力衰竭且2020年1月1日存活的655 919例患者,按既往心衰住院和袢利尿剂使用分为四组。结果显示,40%患者一年内未看心脏科医生,单次心脏科就诊与1年全因死亡绝对降低6%-9%相关,且最佳年随访次数随病情严重程度增加。
要点
- 基于住院史和利尿剂使用的简易分层可有效预测心衰患者结局。
- 40%心衰患者一年内未接受心脏科就诊,与疾病严重程度无关。
- 单次心脏科就诊与1年全因死亡绝对降低6%-9%相关,NNC为11-16。
核心结论
- 尽管诊断为心衰,无论疾病严重程度,40%患者每年未看心脏科医生。
- 基于住院史和利尿剂使用的简易分层能有效预测结局。
- 按此分层调整年心衰咨询次数可优化资源利用并减少可避免的模拟死亡。
研究设计与样本
- 法国全国队列纳入所有既往5年报告心衰且2020年1月1日存活的患者。
- 共纳入655 919例患者,年龄80岁(70-87),48%为女性。
- 按既往心衰住院时间和袢利尿剂使用分为四组:HFH≤1y、HFH>1y、NoHFH/LD+、NoHFH/LD-。
主要发现
- 1年全因死亡风险为15.9%,范围从8.0%(NoHFH/LD-)至25.0%(HFH≤1y)。
- 与NoHFH/LD-相比,NoHFH/LD+死亡风险高1.61倍,HFH>1y高1.83倍,HFH≤1y高2.32倍(P<.0001)。
- 2020年随访第一年,各组心脏科咨询率相似,40%患者缺乏年度就诊。
- 与无咨询相比,2019年单次心脏科就诊与2020年1年全因死亡绝对降低6%-9%相关,所有组一致。
- 预防一例模拟死亡需咨询人数(NNC)为11-16;额外就诊获益随心衰严重程度增加,NNC从55(NoHFH/LD-)至20(HFH≤1y)。
关键数值与推荐
- 最小化死亡数而不增加总咨询次数的最佳随访:NoHFH/LD-为每年1次,NoHFH/LD+和HFH>1y为2-3次,HFH≤1y为4次。
临床怎么用
- 可根据既往心衰住院和利尿剂使用对心衰患者进行简易风险分层。
- 按分层调整每年心脏科随访次数:NoHFH/LD-每年1次,NoHFH/LD+和HFH>1y每年2-3次,HFH≤1y每年4次。
- 应关注并减少心衰患者缺乏年度心脏科就诊的情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Outpatient cardiology follow-up is the cornerstone of heart failure (HF) management, requiring adaptation based on patient severity. However, risk stratification using administrative data is scarce, and the association between follow-up and prognosis according to patient risk has yet to be described at a population level. This study aimed to describe prognosis and management across different strata using simple criteria, including diuretic use and prior HF hospitalization (HFH). METHODS: This nationwide cohort included all French patients reported as having HF in the previous 5 years and alive on 1 January 2020. Patients were categorized into four groups: (i) HFH within the past year (HFH ≤ 1y), (ii) HFH 1-5 years ago (HFH > 1y), (iii) not hospitalized using loop diuretics (NoHFH/LD+), and (iv) not hospitalized without loop diuretics (NoHFH/LD-). Between-group associations, all-cause mortality (ACM), and cardiology follow-up were analysed using survival models. RESULTS: The study included 655 919 patients [80 years (70-87), 48% female]. One-year ACM risk was 15.9%, ranging from 8.0% (NoHFH/LD-) to 25.0% (HFH ≤ 1y). Mortality risk was 1.61-fold higher for NoHFH/LD+, 1.83-fold for HFH > 1y, and 2.32-fold for HFH ≤ 1y compared to NoHFH/LD- (P < .0001). During the first year of follow-up (2020), cardiology consultation rates were similar across groups, with 40% of patients lacking an annual visit. Compared to no consultation, a single cardiology visit in the previous year (2019) was associated with a 6%-9% absolute reduction in 1-year ACM during the following year (2020) across all groups. The number needed to consult (NNC) to prevent one modelled death was 11-16. Additional visits showed greater benefit with increasing HF severity, with NNC ranging from 55 (NoHFH/LD-) to 20 (HFH ≤ 1y). The optimal follow-up to minimize the number of deaths without increasing the total number of consultations was 1 annual visit for NoHFH/LD-, 2-3 visits for NoHFH/LD+ and HFH > 1y, and 4 visits for HFH ≤ 1y patients. CONCLUSIONS: Despite having a HF diagnosis, 40% of patients do not see a cardiologist annually, regardless of disease severity. Simple stratification based on hospitalization history and diuretic use effectively predicts outcomes. Tailoring the annual number of HF consultations according to this stratification could optimize resource use and reduce avoidable modelled deaths.
引用
- Baudry, Pereira, Roubille, et al. Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort. Eur Heart J. 2025. PMID: 40382685. doi:10.1093/eurheartj/ehaf218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。